The Future…

Introduction This month we’ve picked a somewhat broad topic for the blog: The future. What are some of the things that should be on the mind of the forward-thinking supplier of research use only reagents? Of course, this is largely and necessarily speculation, but hopefully somewhat informed! There are two general, interlinked areas to think … Read more


Introduction Among all the ligand bioassays developed, the one which has emerged victorious is the Enzyme Linked Immuno Assay, or ELISA. Variations on the ELISA now have to power to discriminate antigens down to the femtomole/femtogramme (10-18 of a kilogramme) level, depending on how it’s implemented, offering researchers unprecedented levels of sensitivity. Harnessing the power of … Read more

Pivotal Scientific Antibody Market Report 2017

Pivotal Sci 4

Pivotal Scientific Antibody Market Report 2017 Pivotal Scientific is proud to have recently published its fifth annual Antibody Market Report. This year it indicates that there have been substantial changes in the antibody landscape between 2016 and 2017, with the global primary antibodies market growing in worth to $900 million, a significant slice of the … Read more

3 reasons not to blame it on the Antibodies

Antibodies have been pin pointed as the main culprit in the reproducibility issue surrounding the research reagents sector today. However is it too cynical and perhaps plain simplistic to place all the blame on the antibodies alone? Could it be that it is not just the antibodies that are the issue, but the way scientists … Read more

How alternative technologies may be key in future research methods

Following the publication of the human genome it was assumed that life science research for health and disease was a fait accompli, with personalised medicine and a complete understanding of basic biology on the near horizon. Yet this hasn’t quite materialised. Despite definite advances in the life science field, being able to pinpoint and manipulate … Read more